Scarica l'app Stockscreener
14.72
2.77%
-0.42
Precedente Chiudi:
$15.14
Aprire:
$14.92
Volume 24 ore:
778.64K
Relative Volume:
0.40
Capitalizzazione di mercato:
$884.77M
Reddito:
$439.00K
Utile/perdita netta:
$-105.64M
Rapporto P/E:
-8.1778
EPS:
-1.8
Flusso di cassa netto:
$-60.70M
1 W Prestazione:
+6.98%
1M Prestazione:
+4.25%
6M Prestazione:
-44.37%
1 anno Prestazione:
-66.99%
Intervallo 1D:
$14.69
$15.49
Intervallo di 1 settimana:
$12.80
$15.49
Portata 52W:
$12.80
$47.58
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Confronta JANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
14.71 | 910.64M | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.19 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
817.04 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.61 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.10 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Iniziato | Stifel | Buy |
| 2025-09-10 | Iniziato | Truist | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-11 | Iniziato | Raymond James | Outperform |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Finviz
Janux Therapeutics Inks Global Oncology Collaboration With BMS - TipRanks
Janux Therapeutics Signs Exclusive License and Collaboration Agreement With Bristol-Myers Squibb - TradingView — Track All Markets
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading VolumeHere's Why - MarketBeat
Janux Therapeutics Pairs With BMS on Novel Tumor-Activated Therapeutic - Contract Pharma
Key facts: Bristol Myers Squibb signs $850M deal with Janux; partners with Microsoft for AI - TradingView — Track All Markets
BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy - MedCity News
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
BMS bets on Janux’s novel solid tumour therapy through $850m deal - Yahoo Finance
Janux Therapeutics, Inc. Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop A Novel Tumor-Activated Therapeutic for Solid Tumors - marketscreener.com
Bristol Myers buys into Janux’s ‘masked’ T cell engagers - BioPharma Dive
Janux, Bristol Myers Squibb partner on tumor-activated therapy By Investing.com - Investing.com Canada
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits
Janux stock rises after Bristol Myers Squibb collaboration deal By Investing.com - Investing.com UK
Janux stock rises after Bristol Myers Squibb collaboration deal - Investing.com
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace
Janux Therapeutics Secures Exclusive License Agreement with Bristol Myers Squibb, Potential Earnings Up to $800 Million - Intellectia AI
Bristol Myers (BMY) Partners with Janux Therapeutics on Cancer T - GuruFocus
Janux Shares Rise On Solid Tumor License Agreement with Bristol Myers Squibb - marketscreener.com
Bristol Myers inks licensing deal with Janux for cancer therapy - Seeking Alpha
Janux Therapeutics stock soars after Bristol Myers Squibb collaboration By Investing.com - Investing.com Canada
Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy - TradingView — Track All Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Business Wire
Clear Str Downgrades Janux Therapeutics (NASDAQ:JANX) to Hold - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Reaches New 1-Year LowWhat's Next? - MarketBeat
Clear Street downgrades Janux Therapeutics stock to Hold on efficacy concerns - Investing.com Canada
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat
JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target - MSN
Energy Moves: Is Janux Therapeutics Inc part of any ETFQuarterly Market Review & Expert Approved Momentum Ideas - baoquankhu1.vn
Volume Report: What is Janux Therapeutics Inc. s debt to equity ratioJuly 2025 Price Swings & Risk Controlled Daily Plans - baoquankhu1.vn
Moving Averages: How Janux Therapeutics Inc stock reacts to oil pricesWatch List & Advanced Swing Trade Entry Alerts - Bộ Nội Vụ
Risk Report: Can Janux Therapeutics Inc stock reach 100 price targetJuly 2025 Update & Daily Growth Stock Tips - Bộ Nội Vụ
Treasury Yields: Can Janux Therapeutics Inc stock reach 100 price targetWeekly Risk Report & Real-Time Market Sentiment Reports - Bộ Nội Vụ
(JANX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Pullback Watch: Will Janux Therapeutics Inc stock maintain dividend yieldJuly 2025 Weekly Recap & Daily Entry Point Trade Alerts - Bộ Nội Vụ
Will Janux Therapeutics Inc. stock maintain dividend yield2025 Stock Rankings & Capital Efficiency Focused Ideas - Улправда
Aug Retail: Will Janux Therapeutics Inc. stock benefit from upcoming earnings reportsWeekly Trend Summary & Fast Exit Strategy with Risk Control - Улправда
Can Janux Therapeutics Inc. stock deliver sustainable ROEAnalyst Upgrade & Safe Swing Trade Setup Alerts - Улправда
Will Janux Therapeutics Inc. stock benefit from infrastructure spendingMarket Activity Recap & Weekly Setup with ROI Potential - Улправда
Why Janux Therapeutics Inc. stock remains resilientAutomated Trading Signals & Capital Planning and Optimization - Улправда
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
BofA Adjusts Price Target on Janux Therapeutics to $35 From $49, Maintains Buy Rating - marketscreener.com
Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month LowWhat's Next? - MarketBeat
Janux Therapeutics initiated with a Peer Perform at Wolfe Research - MSN
Pre-market Movers: RSLS, STSS, VERO, KTTA... - RTTNews
Janux Therapeutics’ CMO McIver sells $37k in shares By Investing.com - Investing.com India
Andrew Hollman Meyer Sells 1,879 Shares of Janux Therapeutics (NASDAQ:JANX) Stock - MarketBeat
Janux Therapeutics CEO Campbell sells $110k in stock By Investing.com - Investing.com Canada
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.31%
2.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):